As per Cleveland Clinic, primary Raynaud’s phenomenon affects around 5% to 10% of the general population. This phenomenon is predominantly observed among the female population aged 15 to 30 years. Secondary Raynaud’s phenomenon is comparatively more prevalent as its occurrence is associated with the presence of autoimmune diseases. Raynaud’s disease occurs in 90% to 95% of scleroderma patients, 85% of mixed connective tissue disease patients, 40% of systemic lupus erythematous patients and 40% of antisynthetase syndrome patients. The growing prevalence of autoimmune disease thus increases the occurrence of Raynaud’s syndrome, contributing to the overall growth of this market.
For more info @ https://www.credenceresearch.com/report/raynauds-disease-therapeutics-market
According to the National Institute of Health (NIH), 23.5 million Americans have reported to have at least one autoimmune disease. The NIH also reported that the direct healthcare costs associated with autoimmune diseases account to around US$ 100 million. According at a review article published by McFarlane IM et al. (McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, et al. (2018) Gastrointestinal Manifestations of Systemic Sclerosis. Rheumatology (Sunnyvale) 8: 235. doi:10.4172/2161-1149.1000235), the prevalence of scleroderma among the U.S. population accounts to 276 persons per million and incidence rates account to 20 new cases per million each year. The growing prevalence of scleroderma thus contributes to the overall growth of the Raynaud’s disease therapeutic market.
So far, there are no FDA approved treatment options for Raynaud’s disease. Calcium channel blockers, vasodilators and alpha-blockers are prescribed to relieve symptoms. The requirement of a target based therapy remains a major unmet need of this market, thus creating market opportunities for existing and emerging industrial players. The pipeline molecules BAY63-2521 (Riociguat) by Bayer AG and RayVa (Alprostadil) by Apricus Biosciences, Inc., are being developed for Raynaud’s disease treatment, ensuring potential market growth during the forecast period from 2018 to 2026.
Download Sample research report with TOC and Figures @ https://www.credenceresearch.com/sample-request/59154
Raynaud’s disease therapeutics market comprises a vast market outreach across the globe. North America accounted for major market share owing to the growing prevalence of autoimmune conditions leading to Raynaud’s disease, rising research activities and increase healthcare expenditure. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness on healthcare and growing Raynaud’s disease prevalence.
The Global Raynaud’s Disease Therapeutic Market is segmented as follows:
• By Drug Class
o Calcium channel blockers
Nifedipine
Amlodipine
Felodipine
o Alpha blockers
Prazosin
Doxazosin
o Vasodilators
Losartan
Fluoxetine
o Pipeline molecules
BAY63-2521 (Riociguat)
RayVa (Alprostadil)
• By Geography
o North America
United States
Canada
o Europe
United Kingdom
Germany
Rest of Europe
o Asia Pacific
Japan
China
Rest of Asia Pacific
o Latin America
Brazil
Mexico
Rest of Latin America
o Middle East & Africa
GCC
Rest of Middle East & Africa
The global Raynaud’s disease therapeutic market comprises industrial leaders namely, Apricus Biosciences, Inc., Bayer AG, Allergan plc., Covis Pharmaceuticals, Inc., GlaxoSmithKline plc., Zydus Pharma USA,Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd. and others.
Charlie Gefen
Credence Research Inc
gefen.c@credenceresearch.com
https://www.credenceresearch.com